Dr. jeff jones, MD — chief medical officer cullinan therapeutics.

For decades we’ve treated autoimmune diseases by suppressing the immune system — but what if we’ve been approaching the problem all wrong? What if, instead of lifelong immunosuppression, we could selectively eliminate the immune cells causing disease and allow the immune system to rebuild itself? Today we’re exploring one of the hottest areas in biotechnology: T-cell engagers and the possibility of an \.